...Fumiaki Ishibashi; Sho Suzuki; Kentaro Mochida; Takao Tonishi; Yuichi Ishibashi Introduction: Potassium-competitive acid blockers are effective against proton pump inhibitor-refractory gastroesophageal reflux disease; however, their long-term use is associated with economic disadvantages...

... is essential for predicting the curability of early gastric cancer (EGC; R0 resection) before treatment, but the relationship between ulcerative lesions and clinical outcomes remains unclear. We aimed to investigate the effect of proton pump inhibitor (PPI) or potassium-competitive acid blocker (P-CAB...

... discontinuation in the above 92 patients were a proton pump inhibitor (PPI) and vonoprazan (VPZ, a potassium ion competitive acid blocker). Since PPI and VPZ were administered to about the same number of patients, though incidentally, we additionally examined the relationship between patient background factors...

.... Results: EoE showed significant male predominance (82.3%) as compared with EGE (50.0%) ( p < 0.001). Furthermore, patients with EoE were significantly older and had a higher body mass index (24.8 ± 4.0 vs. 22.2 ± 4.3, p < 0.05). Over 90% of the EoE patients were initially given proton pump inhibitor...

... Helicobacter pylori infection who were prescribed antacid medications (potassium-competitive acid blockers, proton pump inhibitors, and/or H 2 receptor antagonist) and had no upper gastrointestinal lesions detected by endoscopy. Methods: This cross-sectional study included the patients who underwent upper...

...Lin Lin; Binxin Cui; You Deng; Xihui Jiang; Wentian Liu; Chao Sun Background and Aims: Proton pump inhibitor (PPI) was widely used in cirrhotic patients with variceal bleeding empirically rather than evidence-based practice. We aimed to evaluate the plausible indication of PPI use in variceal...

... review is to clarify the effectiveness and safety of second-line H. pylori eradication therapy comparing VPZ and proton pump inhibitor (PPI)-based regimens. Methods: Medline (PubMed), EMBASE, Web of Science, Cochrane Library, and the Japan Medical Abstract Society Database were searched. Results: We...

... cause of symptom occurrence in patients with proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD). This study is aimed at clarifying whether the pH value of weakly acidic reflux affects the induction of symptoms. Methods: We retrospectively evaluated the records of combined...

... of vonoprazan (VPZ), a novel potassium-competitive acid blocker, in patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), exhibiting continued pathological esophageal acid exposure (EAE). Methods: Despite ≥8 weeks of appropriate PPI therapy, patients with ­persistent...

...Yasuhisa Sakata; Nanae Tsuruoka; Hironobu Takedomi; Takashi Akutagawa; Ryo Shimoda; Motohiro Esaki; Kazuma Fujimoto Background/Aims: Proton pump inhibitors (PPIs) are widely used for the management of acid-related diseases. This study aimed to clarify the status of PPI use in hospitalized patients...

...Yasuhiro Fujiwara; Atsushi Hashimoto; Risa Uemura; Akinari Sawada; Koji Otani; Fumio Tanaka; Hirokazu Yamagami; Tetsuya Tanigawa; Toshio Watanabe; Daijiro Kabata; Yuko Kuwae; Ayumi Shintani; Masahiko Ohsawa Objective: Recent guidelines propose that both proton pump inhibitor (PPI) responders...

... eradication therapy with vonoprazan or proton pump inhibitors (PPIs). Methods: Between 2012 and 2016, the medical records of 620 patients receiving H. pylori eradication therapy at Saiseikai Karatsu Hospital were evaluated. Patients had received vonoprazan (20 mg) or PPIs with 200 mg clarithromycin and 750 mg...

...Yu Hatano; Ken Haruma; Tomoari Kamada; Akiko Shiotani; Kosuke Takahari; Masatoshi Matsumoto; Osamu Uchida Background/Aims: Previous studies have reported a possible relevance between proton pump inhibitor (PPI) use and 3 new gastric mucosal changes: black spots (BSs), white flat elevated mucosa...

... to in the content or advertisements. 2018 Gastrin Proton pump inhibitor Hypergastrinemia Gastric neuroendocrine cell tumor Gastrin is a key regulator of gastric acid secretion and is secreted by antral G cells. It increases gastric acid secretion by the histamine release from the enterochromaffin...

...Yuichi Kojima; Toshihisa Takeuchi; Makoto Sanomura; Ken Higashino; Keishi Kojima; Kenji Fukumoto; Kou Takata; Hiroki Sakamoto; Masahiro Sakaguchi; Kazunari Tominaga; Kazuhide Higuchi Background/Aim: The long-term administration of proton pump inhibitors (PPIs) is useful for preventing recurrent...

... bowel syndrome Overlap Proton pump inhibitor Health-related quality of life The first line of treatment, either initially or as a long-term maintenance therapy, for treating gastroesophageal reflux disease (GERD) is a proton pump inhibitor (PPI) [ 1 ]. However, it has been reported that 17-32...

...Shu Sahara; Mitsushige Sugimoto; Takahiro Uotani; Hitomi Ichikawa; Mihoko Yamade; Takuma Kagami; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta Background: When administered at a standard dose, proton pump inhibitors (PPIs) do not always provide...

...Hitoshi Sasaki; Akihito Nagahara; Mariko Hojo; Daisuke Asaoka; Kenshi Matsumoto; Taro Osada; Sumio Watanabe Background/Aims: In Japan, a systematic eradication strategy for Helicobacter pylori has been constructed, and consists of a proton pump inhibitor/amoxicillin and clarithromycin (PPI/AC...

... and refractory gastroesophageal reflux disease (GERD) symptoms in patients receiving once daily proton pump inhibitors (PPI) and the efficacy of twice-daily rabeprazole treatment. Method: In a multicenter survey, 433 GERD patients receiving once-daily PPI treatment completed a self-report questionnaire...

...Alike W. van der Velden; Niek J. de Wit; A. Otto Quartero; Diederick E. Grobbee; Mattijs E. Numans Background: Proton pump inhibitor (PPI) therapy reduction after long-term daily treatment for gastro-oesophageal reflux disease (GORD) symptomatology proves difficult in primary care practice. We...